Pharmaceuticals

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...

2024-02-02 22:22 4337

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

2024-02-02 21:30 3592

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

JINAN, China, Feb. 2, 2024 /PRNewswire/ -- On January 29th, the results of the phase II study on Qilu Pharmaceutical's novel anticancer drug iparomlimab and tuvonralimab (QL1706) were published online inSignal Transduction and Targeted Therapy (Impact Factor=39.3). The study investigated the use ...

2024-02-02 17:34 2894

Fapon and Bio Farma Sign MOU for Medical Innovations

DONGGUAN, China, Feb. 2, 2024 /PRNewswire/ -- On February 1, 2024, Fapon, a global leading life science company, andBio Farma, a state-owned pharmaceutical holding company inIndonesia specializing in vaccines, life science products, and other pharmaceuticals, signed a memorandum of understanding ...

2024-02-02 16:30 4614

Xinhua Silk Road: Pien Tze Huang, Beijing Tong Ren Tang agree to boost bilateral cooperation, promote high-quality development of TCM

BEIJING, Feb. 2, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) signed a cooperation agreement with Beijing Tong Ren Tang (TRT) Group during the First Conference of Partners of Tong Ren Tang, which was held inBeijing from January 17 to 19. 

2024-02-02 11:14 3625

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and...

2024-02-01 17:41 3388

EMA Aesthetics Announces a Long-Term Strategic and Equity Partnership with ROHTO Pharmaceutical, Signalling ROHTO's Acceleration into the Global Aesthetics Market

DUBLIN, Feb. 1, 2024 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com ) a global aesthetics company headquartered inDublin, is delighted to announce a strategic and equity partnership with ROHTO Pharmaceutical ( www.rohto.co.jp/global

2024-02-01 16:00 4115

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near Amsterdam Airport Schiphol

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NX Netherlands"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired CEIV Pharma certification (*), a quality certification for pharmaceutical transport established by the International Air Transport As...

2024-02-01 14:00 3830

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive diso...

2024-02-01 01:52 3124

Synbio Tech's Innovative Probiotic Approach Revitalizes Gut and Vaginal Microbiota in Pregnant Women with Candidiasis

KAOHSIUNG, Jan. 31, 2024 /PRNewswire/ -- Innovative research and proprietary technologies have placed Synbio Tech, Inc. (1295:TT) at the forefront of the probiotics field. The company's advancements not only enhance probiotic production efficiency but also significantly benefit intestinal health,...

2024-01-31 09:00 4424

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) an...

2024-01-31 05:46 3069

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 D...

2024-01-30 22:00 2606

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology

JINAN, China, Jan. 30, 2024 /PRNewswire/ -- The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung can...

2024-01-30 16:45 2263

Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF THE CONTACT PERSONS SET OUT BELOW, ONJANUARY 26, 2024, AT 11:20 FINNISH TIME / 10:20 SWEDISH TIME. HELSINKI, ...

2024-01-26 20:08 2432

AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site

* US$223 million expansion will add biologics capacity to AbbVie manufacturing network * Singapore manufacturing site to grow to more than 500 employees following expansion * Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE, Jan. 26, 2024 /PRNews...

2024-01-26 08:30 6982

First International Shipment of HANSIZHUANG Launched

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying anti-PD-1 mAb Zerpidio® (serplulimab, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of benefiting patients worldwide with high-quality biopharmaceuticals...

2024-01-25 21:41 4010

First International Shipment of HANSIZHUANG

SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- On January 25, a truck carrying HANSIZHUANG Zerpidio® (anti-PD-1 monoclonal antibody, Chinese trade name: HANSIZHUANG) slowly left Henlius' Songjiang First Plant. These products, bearing Henlius' mission of "benefiting patients worldwide with high-quality ...

2024-01-25 20:45 6240

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...

2024-01-25 18:38 2751

Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035

SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296,NSE: GLENMARK...

2024-01-25 10:40 3134

PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD

SAN DIEGO, Jan. 25, 2024 /PRNewswire/ -- A recent study published in the Research in Autism Spectrum Disorders unveils groundbreaking solutions for neurodevelopmental disorders. This is the first double-blinded, randomized, placebo-controlledtrial

2024-01-25 10:00 4354
1 ... 84858687888990 ... 184